AzTrials
AzTrials

Kidney TransplantationPhase 2NCT00483756

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

A Phase 2 study testing Cyclosporine and CP-690,550 in people with Kidney Transplantation, run by Pfizer at 69 sites in 15 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Kidney Transplantation
What is being tested?
Cyclosporine and CP-690,550
Could I receive a placebo?
No, everyone receives an active treatment
How many people
338 participants
Where
69 sitesin 15 countries
Study dates
Aug 2007to Apr 2010
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Recipient of a first-time kidney transplant
  • Between the ages of 18 and 70 years, inclusive

Who cannot join

  • Recipient of any non-kidney transplant

Trial locations and contacts

69 sites in 15 countries.

69 sites in 15 countries

United States37 sites
  • Pfizer Investigational Site

    Ann Arbor, Michigan, 48109

  • Pfizer Investigational Site

    Aurora, Colorado, 80045

  • Pfizer Investigational Site

    Baltimore, Maryland, 21201

  • Pfizer Investigational Site

    Boston, Massachusetts, 02215

  • Pfizer Investigational Site

    Chapel Hill, North Carolina, 27514

  • Pfizer Investigational Site

    Chapel Hill, North Carolina, 27599-7155

  • Pfizer Investigational Site

    Chapel Hill, North Carolina, 27599-7211

  • Pfizer Investigational Site

    Chapel Hill, North Carolina, 27599-7360

  • Pfizer Investigational Site

    Charleston, South Carolina, 29425

  • Pfizer Investigational Site

    Chicago, Illinois, 60611

  • Pfizer Investigational Site

    Chicago, Illinois, 60637

  • Pfizer Investigational Site

    Dallas, Texas, 75204

  • Pfizer Investigational Site

    Dallas, Texas, 75246

  • Pfizer Investigational Site

    Detroit, Michigan, 48202

  • Pfizer Investigational Site

    Fort Worth, Texas, 76104

  • Pfizer Investigational Site

    Gainesville, Florida, 32610

  • Pfizer Investigational Site

    Gainsville, Florida, 32610

  • Pfizer Investigational Site

    Little Rock, Arkansas, 72205

  • Pfizer Investigational Site

    Livingston, New Jersey, 07039

  • Pfizer Investigational Site

    Los Angeles, California, 90048

  • Pfizer Investigational Site

    Los Angeles, California, 90095

  • Pfizer Investigational Site

    New Haven, Connecticut, 06504

  • Pfizer Investigational Site

    New Haven, Connecticut, 06510

  • Pfizer Investigational Site

    New York, New York, 10029

  • Pfizer Investigational Site

    Palo Alto, California, 94304

  • Pfizer Investigational Site

    Philadelphia, Pennsylvania, 19102

  • Pfizer Investigational Site

    Portland, Oregon, 97239

  • Pfizer Investigational Site

    Rochester, Minnesota, 55905

  • Pfizer Investigational Site

    San Diego, California, 92123

  • Pfizer Investigational Site

    San Francisco, California, 94115

  • Pfizer Investigational Site

    San Francisco, California, 94143

  • Pfizer Investigational Site

    Springfield, Massachusetts, 01107

  • Pfizer Investigational Site

    Springfield, Massachusetts, 01199

  • Pfizer Investigational Site

    St Louis, Missouri, 63110

  • Pfizer Investigational Site

    Stanford, California, 94305

  • Pfizer Investigational Site

    Tampa, Florida, 33606

  • Pfizer Investigational Site

    Valhalla, New York, 10595

Other trials in United States

Australia6 sites
  • Pfizer Investigational Site

    Adelaide, South Australia, 5000

  • Pfizer Investigational Site

    Camperdown, New South Wales, 2050

  • Pfizer Investigational Site

    Clayton, Victoria, 3168

  • Pfizer Investigational Site

    Parkville, Victoria, 3050

  • Pfizer Investigational Site

    Westmead, New South Wales, 2145

  • Pfizer Investigational Site

    Woodville, South Australia, 5011

Other trials in Australia

France4 sites
  • Pfizer Investigational Site

    Nantes, 44093

  • Pfizer Investigational Site

    Paris, 75743

  • Pfizer Investigational Site

    Toulouse, 31059

  • Pfizer Investigational Site

    Vandœuvre-lès-Nancy, 54500

Other trials in France

Brazil3 sites
  • Pfizer Investigational Site

    Porto Alegre, Rio Grande do Sul, 90020-090

  • Pfizer Investigational Site

    São Paulo, São Paulo, 04038-002

  • Pfizer Investigational Site

    São Paulo, São Paulo, 04039-050

Other trials in Brazil

South Korea3 sites
  • Pfizer Investigational Site

    Seoul, 110-744

  • Pfizer Investigational Site

    Seoul, 120-752

  • Pfizer Investigational Site

    Seoul, 138-736

Other trials in South Korea

Belgium2 sites
  • Pfizer Investigational Site

    Anderlecht, 1070

  • Pfizer Investigational Site

    Leuven, 3000

Other trials in Belgium

Germany2 sites
  • Pfizer Investigational Site

    Berlin, 10117

  • Pfizer Investigational Site

    Hamburg, 20246

Other trials in Germany

Italy2 sites
  • Pfizer Investigational Site

    Bologna, 40138

  • Pfizer Investigational Site

    Roma, 00168

Other trials in Italy

Poland2 sites
  • Pfizer Investigational Site

    Warsaw, 02-006

  • Pfizer Investigational Site

    Wroclaw, 50-417

Other trials in Poland

Portugal2 sites
  • Pfizer Investigational Site

    Coimbra, 3000-075

  • Pfizer Investigational Site

    Lisbon, 1069-166

Other trials in Portugal

Spain2 sites
  • Pfizer Investigational Site

    Barcelona, Barcelona, 08036

  • Pfizer Investigational Site

    L'Hospitalet de Llobregat, Barcelona, 08907

Other trials in Spain

Canada1 site
  • Pfizer Investigational Site

    Edmonton, Alberta, T6G 2B7

Other trials in Canada

Czechia1 site
  • Pfizer Investigational Site

    Prague, 140 21

Other trials in Czechia

Netherlands1 site
  • Pfizer Investigational Site

    Rotterdam, 3015 GD

Other trials in Netherlands

Norway1 site
  • Pfizer Investigational Site

    Oslo, 0027

Other trials in Norway

About this study

Official title: A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-administration of CP-690,550 and Mycophenolate Mofetil / Mycophenolate Sodium in De Novo Renal Allograft Recipients

A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months. Patients will be assigned to one of three treatment groups after receiving a kidney transplant. Two of the treatment groups will receive 2 different dosing regimens of the JAK3 inhibitor that will be taken by mouth. The third treatment group will be a standard-of-care control arm. Patients will continue to take the assigned study medication for 12 months as well as other standard transplant medications such as prednisone.

Being tested
Cyclosporine, CP-690,550
Keywords
Immunosuppression, JAK3 inhibitor, kidney transplantation.

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CyclosporineDrug

    Standard of care

  • CP-690,550Drug

    CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12

  • CP-690,550Drug

    CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12

Study groups in NCT00483756
Study groupRoleWhat they receive
1Active comparatorTreatment Arm 1 will also receive standard of care medications
Receives: Drug: Cyclosporine
2ExperimentalTreatment Arm 2 will also receive standard of care medications
Receives: Drug: CP-690,550
3ExperimentalTreatment Arm 3 will also receive standard of care medications
Receives: Drug: CP-690,550

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant

    Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of >= 0.3 milligram per deciliter (mg/dL) and >=20 percent (%) from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hours (hrs) of the time of biopsy.

    Measured: Baseline up to Month 6

  2. Glomerular Filtration Rate (GFR) at Month 12

    GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is greater than (>) 90 milliliter per minute (mL/min), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (<) 15 mL/min indicated kidney failure.

    Measured: 2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 12

Secondary outcomes (18)
  1. Glomerular Filtration Rate (GFR) at Month 6

    GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.

    Measured: 2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 6

  2. Number of Participants With Progression of Chronic Allograft Lesions at Month 12

    Progression of chronic allograft lesions was defined as an increase in the Banff chronicity score (Banff-CS) in biopsy from the implantation (baseline) biopsy in a given participant. Banff-CS was the sum of the Banff scores for the 4 chronic basic lesions (allograft glomerulopathy [cg] + interstitial fibrosis [ci] + tubular atrophy [ct] + vascular intimal thickening [cv]).The Banff-CS ranged from 0-12, higher score indicated greater lesions and Month 12 Banff-CS greater than the implantation biopsy score indicated progression of lesions.

    Measured: Month 12

  3. Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) 12 Months Post Transplant

    Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of >= 0.3 mg/dL and >=20% from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hrs of the time of biopsy.

    Measured: Baseline up to Month 12

  4. Number of Participants With Treated Clinical Acute Rejection

    Treated clinical acute rejection was defined as an acute rejection episode that was diagnosed based on local biopsy readout and received anti-rejection treatment.

    Measured: Month 6, 12

  5. Number of Participants With Combined Banff Rejection Categories (Categories 2, 3, and 4)

    Banff 97: standard classification for scoring and classifying rejection of kidney transplant biopsies in 6 diagnostic categories: normal, antibody-mediated rejection, borderline changes: 'suspicious' for acute cellular rejection, acute/active cellular rejection, chronic/sclerosing allograft nephropathy, and other. Combined Banff rejection calculated from categories of antibody-mediated rejection (Category 2) plus borderline changes (Category 3) plus acute rejection (Category 4), as interpreted by the central pathologist.

    Measured: Month 6, 12

  6. Number of Participants With Graft Loss

    Graft loss was defined as graft nephrectomy, participant death, re-transplantation, or return to dialysis for >=6 consecutive weeks.

    Measured: Month 6, 12

  7. Number of Participants With Efficacy Failure

    Efficacy failure was the first occurrence of clinical BPAR diagnosed by the central pathologist or graft loss including participant death.

    Measured: Month 6, 12

  8. Number of Participants Who Died

    Measured: Month 6, 12

  9. Lymphocyte Subset

    The absolute cell counts of cluster of differentiation 3 (CD3): T-lymphocytes, cluster of differentiation 19 (CD19): B-lymphocytes, and cluster of differentiation 56 (CD56): assumed natural killer cells, were determined using flow cytometry.

    Measured: Month 1, 3, 6, 12

  10. Population Pharmacokinetics (PK)

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Measured: Pre-dose-2(P-2), Pre-dose(P), 0.5,1,2 hr post-dose(PD) on Day14, Month(M) 3; P,1,2 hr PD on M1; P, 0.5, 2, 4 hr PD on M6; P-2, P, 0.5 hr PD on M9, M12 as per randomization in CP-690,550 treated; P on M3 and P, 2, 4 hr PD on M6 in CsA treated participants

  11. Glomerular Filtration Rate (GFR) by The Nankivell Equation

    GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated was estimated by creatinine clearance (CLcr) using Nankivell equation. CLcr by Nankivell equation= (6.7 per serum creatinine) plus (0.25*body weight) minus (0.5*serum urea) minus (100 per height square) plus (35 for male/25 for female). A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.

    Measured: Month 1, 3, 6, 9, 12

  12. Glomerular Filtration Rate (GFR) by The Cockcroft-Gault Equation

    GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using Cockcroft-Gault equation. GFR by Cockcroft-Gault equation= body weight*(140 minus age in years) divided by (72*serum creatinine). For females value obtained was multiplied by 0.85. A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.

    Measured: Month 1, 3, 6, 9, 12

  13. Glomerular Filtration Rate (GFR) by The Modification of Diet in Renal Disease (MDRD) Equation

    GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using MDRD equation. GFR by MDRD equation = 170 * (serum creatinine)^(-0.999) * (age in years)^(-0.176) * (0.762 if female) * (1.18 if black) * (blood urea nitrogen concentration)^(-0.170) * (serum albumin concentration)^(0.318).A normal GFR is >90 mL/min/1.73 square meter (m^2), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min/1.73 m^2 indicated kidney failure.

    Measured: Month 1, 3, 6, 9, 12

  14. Glomerular Filtration Rate (GFR) by The Abbreviated Modification of Diet in Renal Disease (MDRD) Equation

    GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using abbreviated MDRD equation. GFR by abbreviated MDRD equation= 186 * (serum creatinine)^(-1.154) * (age in years)^(-0.203) * (0.742 if female) * (1.210 if black). A normal GFR is >90 mL/min/1.73 m^2, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min/1.73 m^2 indicated kidney failure.

    Measured: Month 1, 3, 6, 9, 12

  15. Number of Participants With Clinically Significant Infections

    Clinically significant infection was defined as the presence of documented infection confirmed by culture, biopsy, genomic, or serologic findings post-randomization and requiring hospitalization or parenteral anti-infective treatment, or otherwise deemed significant by the investigator.

    Measured: Baseline up to Month 12

  16. 36-Item Short-Form Health Survey (SF-36)

    SF-36: standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores. Total of 11 variables were analyzed (8 subscales,2 composite subscales and Question(Q) 2 "how would you rate your health in general now?"(range 1=better, 5=worst). The score for a section (except Q2) is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Measured: Baseline, Month 6, 12

  17. End-Stage Renal Disease Symptom Checklist Transplantation Module (ESRD-SCL)

    ESRD-SCL:43-item disease specific self-administered questionnaire. Participants' rated question"At the moment,how much do you suffer?"for each item on 5 point scale,ranged (Ra) 0(not at all)to 4(extremely).Consisted of 6 subscales:cardiac and renal dysfunction;Ra 0-28,increased(In) growth of gum and hair;Ra 0-20,limited cognitive capacity;Ra 0-32,limited physical capacity;Ra 0 - 40,side effects (SEs) of corticosteroids;Ra 0-20,transplantation associated psychological distress(TAPD);Ra 0-32(higher scores=greater dysfunction for each subscale).Total score:0-172,higher scores=greater dysfunction.

    Measured: Baseline, Month 6, 12

  18. Severity of Dyspepsia Assessment (SODA)

    SODA:17-item health scale, assessed participant-reported perceptions of dyspepsia;consists of 3 subscales:Pain Intensity (6-items to assess pain and intensity of abdominal [Ab] discomfort; Range (Ra):2-47, higher score= greater pain and Ab discomfort), Non-Pain Symptoms (7-items to assess severity and impact of non-pain symptoms:burping/belching,heartburn,bloating,flatulence,sour taste,nausea,and bad breath; Ra:7-35,higher scores = increased symptom severity and influence), and Satisfaction (4-items to assess degree of satisfaction with Ab discomfort; Ra:2-23,higher scores= more satisfaction).

    Measured: Baseline, Month 6, 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jun 2007 (estimated)
  2. Study startAug 2007
  3. Primary completionFeb 2010
  4. Study completionApr 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
338 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00483756
Sponsor's protocol ID
A3921030
Status last verified
Feb 2013
First submitted
6 Jun 2007
Last updated
14 Mar 2013
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Cyclosporine and CP-690,550 in people with Kidney Transplantation, run by Pfizer at 69 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 69 sites in United States, Australia, France, Brazil, South Korea and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 14 Mar 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant (time frame: Baseline up to Month 6). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in